Efficacy of Ferric Carboxymaltose (Ferinject®) in Anemic Patients Anticipating Pancreatoduodenectomy

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

April 27, 2020

Study Completion Date

April 27, 2020

Conditions
Pancreatic CancerAnemia
Interventions
DRUG

Ferinject (Ferric Carboxymaltose)

"Ferinject® to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight \<50 Kg .~Study drug may be administered as IV drip infusion or IV undiluted bolus injection."

Trial Locations (1)

410-769

National Cancer Center, Goyang-si

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

JW Pharmaceutical

INDUSTRY

lead

National Cancer Center, Korea

OTHER_GOV

NCT02628860 - Efficacy of Ferric Carboxymaltose (Ferinject®) in Anemic Patients Anticipating Pancreatoduodenectomy | Biotech Hunter | Biotech Hunter